Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. Started in 1983 with five psychiatry products, it is now India's largest chronic prescription drug company and a market leader in several therapeutic areas. In 2015, its acquisition of Ranbaxy made it the largest pharmaceutical company in India. The presentation concludes that Sun Pharmaceuticals is performing well financially, has significant potential for growth, and as the world's 5th largest pharmaceutical company after acquiring Ranbaxy, it is recommended for investment.

1. COMPANY REVIEW
SESSION
PRESENTED BY-
MONIKA LOHIA (D-54)

2. GROWING TOGETHER
• Sun Pharmaceutical Industries
Limited (NSE: SUNPHARMA, BSE: 524715)
is
• An Indian multinational pharmaceutical
company headquartered in Mumbai.
• Manufactures and sells pharmaceutical
formulations and active pharmaceutical
ingredients (APIs) primarily in India and the
United States.

3. OVERVIEW
• Started as partnership firm by Mr. Dilip Shanghavi in 1983
in Vapi with just five products to treat psychiatry ailments.
• Cardiology products were introduced in 1987 followed
by gastroenterology products in 1989.
• Today it is the largest chronic prescription company in
India and a market leader in psychiatry, neurology,
cardiology, orthopaedics, ophthalmology,
gastroenterology and nephrology.
• The 2015 acquisition of Ranbaxy has made the company
the largest pharma company in India

5. KEY PEOPLE

6. CREATING VALUE

7. LEADERSHIP IN KEY
THERAPEUTIC AREAS

8. KEY ACQUISITIONS

9. KEY PERFORMANCE INDICATORS

10. SPENDING DISTRIBUTION
(GEOGRAPHY WISE)

11. GLOBAL MANUFACTURING
FOOTPRINTS

12. SHARE HOLDINGS

13. STOCK MARKET

14. BALANCE SHEET

16. PROFIT AND LOSS STATEMENT

17. FINANCIAL RATIOS

19. RECENT NEWS
• March 8, 2016- Sun Pharma signs M S Dhoni
as Revital H brand ambassador
• Feb 12, 2016- Sun Pharma Q3 net profit
surges over 3-fold to Rs 1,417 crore
• Jan 29, 2016- Sun Pharmaceuticals to sell
some low priority Ranbaxy brands
• Dec 19, 2015- U.S. FDA warns Sun Pharma
over standards at Halol plant (Gujrat)
• Sep 1 2015- Sun Pharma completes
acquisition of GSK Australia opiates biz

20. CONCLUSION
Sun pharmaceuticals is performing well
financials show that the company has huge
scope of growth.
After acquiring Ranbaxy it has become 5th
largest pharmaceutical company in the world.
So it is recommended to invest in this
company.

21. ANY QUESTIONS ?